NONPROFIT, NONPARTISAN PLATFORM OF ACCURATE SCIENCE-BASED SOLUTIONS TO COVID-19

Browsing: PROFILES (Under Construction)

Profiles of Virus Project member companies and projects

Co-Diagnostics offers a range of products and services to suit the needs of diagnostics laboratories, research institutions, and enterprises across the globe that rely on PCR technology. Co-Diagnostics was founded with a simple but ambitious goal: to bring high-quality molecular diagnostics for infectious diseases to areas and populations of the world that need them most. Since that time, Co-Diagnostics researchers have developed additional applications far beyond the detection of infectious diseases.

This modified PCR test overcomes the invasiveness of doing a nasal swab to detect the presence of the virus in the viral RNA, detected in saliva . Mirimus has taken the saliva test version of PCR tests into what I call large scale testing, you know, thousands of patients per day. The testing is done in pools, on the pools can be anything greater than two quickly and done overnight you can clear a whole group and you are then able to look at groups of individuals without violating the HIPAA rules and testing rules that state various states have.…

Mature pipeline of biopharmaceuticals for rare diseases. Government funding for biodefense business. Soligenix is a two-segment business. They have a biotherapeutics rare disease segment focused on cancer, cancer supportive care and inflammation and a separate vaccine/biodefense segment of business funded entirely by the U.S. government, focused on medical countermeasures for military and civilian use. See Soligenix’s Profile.

A new diagnostic technology can predict how patients will respond different drugs or drug combinations before the patients take the drugs. Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer. This revolutionary diagnostic test will enable oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells. See Travera’s Profile.